Developer docs
API playgroundTry for free, no card

Search company profiles

Cardiff Oncology

Full company profile

uuid0002jfm

Namestring
Cardiff Oncology
Legal namestring
Cardiff Oncology, Inc.
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Cardiff Oncology, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, developing small-molecule inhibitors of PLK1 (Polo-Like Kinase 1) for the treatment of cancer. The company's lead asset, onvansertib, is an oral PLK1 inhibitor designed to exploit tumor dependence on PLK1-mediated DNA damage repair, thereby enhancing the activity of standard-of-care chemotherapy and targeted agents. The company's core program targets first-line RAS-mutated metastatic colorectal cancer (mCRC), an indication representing approximately 45-50% of colorectal cancer patients with limited effective treatment options. Beyond the lead mCRC program, onvansertib is being evaluated through investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), triple-negative breast cancer, small cell lung cancer, ovarian cancer, chronic myelomonocytic leukemia, metastatic castration-resistant prostate cancer, and medulloblastoma, in collaboration with academic centers including Mayo Clinic, Oregon Health & Science University, Dana-Farber Cancer Institute, and the University of Colorado.

The company has no commercial products and operates in a pre-revenue clinical development posture. Q1 2026 reported revenue was approximately $240,000, with a Q1 2026 net loss of $12.3 million and a full-year 2025 net loss of $45.9 million. As of March 31, 2026, cash, cash equivalents, and short-term investments stood at $46.1 million, providing stated runway into Q1 2027 excluding Phase 3 costs. The capital structure is supplemented by a $15 million strategic investment and CRO services partnership with Pfizer supporting the planned global registrational Phase 3 CRDF-005 trial, while Cardiff retains full program rights to onvansertib. A December 2024 financing raised approximately $40 million.

The business model is contingent on successful Phase 3 execution, FDA approval, and either self-commercialization or partnership-based monetization. The company is publicly listed on NASDAQ under ticker CRDF, with a market capitalization of approximately $129.9 million as of early June 2026 and a consensus analyst price target of $10.10. Notable risks include an active license dispute with Nerviano Medical Sciences over onvansertib intellectual property, limited near-term cash runway relative to Phase 3 funding requirements, and binary clinical-trial outcomes.

Short descriptiontext

Cardiff Oncology is a clinical-stage biopharmaceutical company developing onvansertib, an oral PLK1 inhibitor, primarily for first-line RAS-mutated metastatic colorectal cancer, with additional investigator-initiated programs across multiple solid tumor and hematologic indications. It is publicly listed on NASDAQ as CRDF and has no commercial products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
PLK1 inhibitor therapy, oncology drug development, clinical stage biotechnology, kinase inhibitor drugs, metastatic colorectal cancer
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 (Polo-Like Kinase 1) inhibitor designed to be combined with standard-of-care chemotherapy and targeted therapies across multiple cancer indications. The lead program targets first-line RAS-mutated metastatic colorectal cancer in combination with FOLFIRI/bevacizumab, advancing toward a global registrational Phase 3 trial, with additional investigator-initiated programs in pancreatic, breast, lung, ovarian, prostate cancers, and CMML.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 72.2% confirmed objective response rate (ORR) at 30 mg dose vs 43.2% for standard-of-care in first-line RAS-mutated mCRC (Phase 2 CRDF-004 trial)
+4 more records
Product overview1 text field

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies. The company's primary product is onvansertib, an oral PLK1 inhibitor evaluated in combination with standard-of-care therapeutics across multiple clinical programs targeting RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), chronic myelomonocytic leukemia (CMML), small cell lung cancer, triple-negative breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and ovarian cancer. The company operates clinical programs including the CRDF-004 Phase 2 randomized trial for first-line RAS-mutated mCRC treatment.

Product and service1 record
1Onvansertib
CategoryOncology Therapeutics / PLK1 Inhibitor
Description

Onvansertib is an oral PLK1 (Polo-like kinase 1) inhibitor being evaluated in combination with standard-of-care therapeutics across multiple cancer indications. It targets tumor vulnerabilities to overcome treatment resistance by inhibiting PLK1's ability to repair DNA damage caused by chemotherapy and targeted cancer drugs. Lead indication is first-line RAS-mutated metastatic colorectal cancer in combination with FOLFIRI/bevacizumab.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-06-05
Description

Nerviano Medical Sciences previously held a license agreement for onvansertib. On May 27, 2026, Nerviano terminated the license citing material breach including failure to correct patent inventorship to include a Nerviano employee and failure to use commercially reasonable efforts to develop onvansertib and obtain regulatory approvals. Cardiff responded with a lawsuit challenging the termination.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Mayo Clinic, specifically Mrinal Patnaik who leads the Acute Leukemia and Myeloid Neoplasms group, is leading an investigator-initiated trial of onvansertib single-agent clinical activity in chronic myelomonocytic leukemia (CMML). Mayo Clinic logo appears in Cardiff's pipeline page alongside other academic collaborators.

3Oregon Health & Science University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Oregon Health & Science University (OHSU) is listed in Cardiff's onvansertib pipeline, collaborating on investigator-initiated trials for onvansertib in metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone.

cardiffoncology.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dana-Farber Cancer Institute is listed in Cardiff's pipeline as a collaborator on onvansertib investigator-initiated trials, likely in the ovarian cancer/PARP inhibitor combination program.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

University of Colorado (Denver) is listed in Cardiff's pipeline as a collaborator, contributing to medulloblastoma investigator-initiated trials combining onvansertib with radiation therapy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Revolution Medicines is a clinical-stage oncology company developing RAS(ON) inhibitors targeting KRAS G12C, G12D, and pan-RAS variants. It is the most direct comparator to Cardiff given shared focus on RAS-driven cancers and similar clinical-stage, single-mechanism-platform profile.

TypeDirect peer
Description

Erasca is a clinical-stage precision oncology company developing a portfolio of RAS/MAPK pathway-targeting therapies for RAS-mutated solid tumors. Like Cardiff, it focuses on addressing RAS-driven cancers through differentiated mechanisms and operates at similar clinical-stage scale.

TypeDirect peer
Description

Mirati Therapeutics developed Krazati (adagrasib), a KRAS G12C inhibitor, and was acquired by Bristol Myers Squibb. Its commercial-stage RAS oncology franchise overlaps directly with Cardiff's RAS-mutated mCRC focus and represents the leading competitive benchmark for PLK1 inhibitor combinations.

TypeDirect peer
Description

BridgeBio is a clinical-stage biopharmaceutical company developing RAS-pathway and oncology therapeutics alongside its rare disease portfolio. Its oncology programs targeting KRAS-driven cancers and similar clinical-development-stage profile make it a relevant comparable.

TypeDirect peer
Description

Foghorn Therapeutics is a clinical-stage oncology company developing precision medicines targeting the chromatin regulatory system. While mechanistically distinct, its similar market cap, clinical-stage profile, and oncology focus make it a relevant peer.

TypeDirect peer
Description

Kronos Bio is a clinical-stage oncology company developing therapies targeting dysregulated transcription and signaling pathways in cancer. Its similar small-cap, clinical-stage profile and oncology pipeline orientation make it a relevant comparable.

TypeDirect peer
Description

Black Diamond Therapeutics is a clinical-stage precision oncology company developing allosteric mutation-targeted therapies. Its similar market capitalization, clinical-stage profile, and focus on oncogene-driven cancers make it a relevant peer comparable.

TypeBroad incumbent
Description

Amgen is a global biopharmaceutical incumbent with the commercialized KRAS G12C inhibitor Lumakras (sotorasib). It competes broadly in the RAS-mutated oncology space and serves as the dominant commercial benchmark for any approved RAS-pathway therapy in mCRC.

TypeBroad incumbent
Description

Roche is a global oncology leader with established colorectal cancer franchises including bevacizumab (Avastin). Its incumbent position in 1L mCRC combination therapy makes it a strategic reference for any new agent seeking to combine with FOLFIRI/bevacizumab.

TypeBroad incumbent
Description

Pfizer is a global biopharmaceutical incumbent that has invested $15M and serves as CRO partner for Cardiff's Phase 3 trial. While already a strategic partner rather than pure competitor, it overlaps in oncology drug development and remains a likely acquirer or commercialization partner if onvansertib succeeds.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cardiff Oncology

Oncology Therapeuticscardiffoncology.com

Cardiff Oncology is a clinical-stage biopharmaceutical company developing onvansertib, an oral PLK1 inhibitor, primarily for first-line RAS-mutated metastatic colorectal cancer, with additional investigator-initiated programs across multiple solid tumor and hematologic indications. It is publicly listed on NASDAQ as CRDF and has no commercial products.

What Cardiff Oncology does

Cardiff Oncology, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, developing small-molecule inhibitors of PLK1 (Polo-Like Kinase 1) for the treatment of cancer. The company's lead asset, onvansertib, is an oral PLK1 inhibitor designed to exploit tumor dependence on PLK1-mediated DNA damage repair, thereby enhancing the activity of standard-of-care chemotherapy and targeted agents. The company's core program targets first-line RAS-mutated metastatic colorectal cancer (mCRC), an indication representing approximately 45-50% of colorectal cancer patients with limited effective treatment options. Beyond the lead mCRC program, onvansertib is being evaluated through investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), triple-negative breast cancer, small cell lung cancer, ovarian cancer, chronic myelomonocytic leukemia, metastatic castration-resistant prostate cancer, and medulloblastoma, in collaboration with academic centers including Mayo Clinic, Oregon Health & Science University, Dana-Farber Cancer Institute, and the University of Colorado.

The company has no commercial products and operates in a pre-revenue clinical development posture. Q1 2026 reported revenue was approximately $240,000, with a Q1 2026 net loss of $12.3 million and a full-year 2025 net loss of $45.9 million. As of March 31, 2026, cash, cash equivalents, and short-term investments stood at $46.1 million, providing stated runway into Q1 2027 excluding Phase 3 costs. The capital structure is supplemented by a $15 million strategic investment and CRO services partnership with Pfizer supporting the planned global registrational Phase 3 CRDF-005 trial, while Cardiff retains full program rights to onvansertib. A December 2024 financing raised approximately $40 million.

The business model is contingent on successful Phase 3 execution, FDA approval, and either self-commercialization or partnership-based monetization. The company is publicly listed on NASDAQ under ticker CRDF, with a market capitalization of approximately $129.9 million as of early June 2026 and a consensus analyst price target of $10.10. Notable risks include an active license dispute with Nerviano Medical Sciences over onvansertib intellectual property, limited near-term cash runway relative to Phase 3 funding requirements, and binary clinical-trial outcomes.

Cardiff Oncology firmographics

Firmographics
Name
Cardiff Oncology
Legal name
Cardiff Oncology, Inc.
Website
https://cardiffoncology.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Cardiff Oncology is a clinical-stage biopharmaceutical company developing onvansertib, an oral PLK1 inhibitor, primarily for first-line RAS-mutated metastatic colorectal cancer, with additional investigator-initiated programs across multiple solid tumor and hematologic indications. It is publicly listed on NASDAQ as CRDF and has no commercial products.
Ownership category
akta.pro rank

Cardiff Oncology industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • PLK1 inhibitor therapy
  • Oncology drug development
  • Clinical stage biotechnology
  • Kinase inhibitor drugs
  • Metastatic colorectal cancer

Where Cardiff Oncology is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cardiff Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels6 records

Cardiff Oncology product offering

Product offering

Core offering

Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 (Polo-Like Kinase 1) inhibitor designed to be combined with standard-of-care chemotherapy and targeted therapies across multiple cancer indications. The lead program targets first-line RAS-mutated metastatic colorectal cancer in combination with FOLFIRI/bevacizumab, advancing toward a global registrational Phase 3 trial, with additional investigator-initiated programs in pancreatic, breast, lung, ovarian, prostate cancers, and CMML.

Product overview

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies. The company's primary product is onvansertib, an oral PLK1 inhibitor evaluated in combination with standard-of-care therapeutics across multiple clinical programs targeting RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), chronic myelomonocytic leukemia (CMML), small cell lung cancer, triple-negative breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and ovarian cancer. The company operates clinical programs including the CRDF-004 Phase 2 randomized trial for first-line RAS-mutated mCRC treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Onvansertib Onvansertib is an oral PLK1 (Polo-like kinase 1) inhibitor being evaluated in combination with standard-of-care therapeutics across multiple cancer indications. It targets tumor vulnerabilities to overcome treatment resistance by inhibiting PLK1's ability to repair DNA damage caused by chemotherapy and targeted cancer drugs. Lead indication is first-line RAS-mutated metastatic colorectal cancer in combination with FOLFIRI/bevacizumab.

Quantifiable outcome

  • 72.2% confirmed objective response rate (ORR) at 30 mg dose vs 43.2% for standard-of-care in first-line RAS-mutated mCRC (Phase 2 CRDF-004 trial)
  • +4 more outcomes

Companies that use Cardiff Oncology

Customer profile

Segments3 records

Ideal customer profiles3 records

Cardiff Oncology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Cardiff Oncology partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Nerviano Medical SciencescoreOEM/ Whitelabel/ Licensing Partner · 5 June 2026Nerviano Medical Sciences previously held a license agreement for onvansertib. On May 27, 2026, Nerviano terminated the license citing material breach including failure to correct patent inventorship to include a Nerviano employee and failure to use commercially reasonable efforts to develop onvansertib and obtain regulatory approvals. Cardiff responded with a lawsuit challenging the termination.
  • Mayo ClinicminorStrategic or Co-development PartnerMayo Clinic, specifically Mrinal Patnaik who leads the Acute Leukemia and Myeloid Neoplasms group, is leading an investigator-initiated trial of onvansertib single-agent clinical activity in chronic myelomonocytic leukemia (CMML). Mayo Clinic logo appears in Cardiff's pipeline page alongside other academic collaborators.
  • Oregon Health & Science UniversityminorStrategic or Co-development PartnerOregon Health & Science University (OHSU) is listed in Cardiff's onvansertib pipeline, collaborating on investigator-initiated trials for onvansertib in metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone.
  • Dana-Farber Cancer InstituteminorStrategic or Co-development PartnerDana-Farber Cancer Institute is listed in Cardiff's pipeline as a collaborator on onvansertib investigator-initiated trials, likely in the ovarian cancer/PARP inhibitor combination program.
  • University of Colorado (Denver)minorStrategic or Co-development PartnerUniversity of Colorado (Denver) is listed in Cardiff's pipeline as a collaborator, contributing to medulloblastoma investigator-initiated trials combining onvansertib with radiation therapy.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Cardiff Oncology competitors and assessment

Company assessment

Direct peers

  • Revolution Medicines: Revolution Medicines is a clinical-stage oncology company developing RAS(ON) inhibitors targeting KRAS G12C, G12D, and pan-RAS variants. It is the most direct comparator to Cardiff given shared focus on RAS-driven cancers and similar clinical-stage, single-mechanism-platform profile.
  • Erasca: Erasca is a clinical-stage precision oncology company developing a portfolio of RAS/MAPK pathway-targeting therapies for RAS-mutated solid tumors. Like Cardiff, it focuses on addressing RAS-driven cancers through differentiated mechanisms and operates at similar clinical-stage scale.
  • Mirati Therapeutics: Mirati Therapeutics developed Krazati (adagrasib), a KRAS G12C inhibitor, and was acquired by Bristol Myers Squibb. Its commercial-stage RAS oncology franchise overlaps directly with Cardiff's RAS-mutated mCRC focus and represents the leading competitive benchmark for PLK1 inhibitor combinations.
  • BridgeBio Pharma: BridgeBio is a clinical-stage biopharmaceutical company developing RAS-pathway and oncology therapeutics alongside its rare disease portfolio. Its oncology programs targeting KRAS-driven cancers and similar clinical-development-stage profile make it a relevant comparable.
  • Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage oncology company developing precision medicines targeting the chromatin regulatory system. While mechanistically distinct, its similar market cap, clinical-stage profile, and oncology focus make it a relevant peer.
  • Kronos Bio: Kronos Bio is a clinical-stage oncology company developing therapies targeting dysregulated transcription and signaling pathways in cancer. Its similar small-cap, clinical-stage profile and oncology pipeline orientation make it a relevant comparable.
  • Black Diamond Therapeutics: Black Diamond Therapeutics is a clinical-stage precision oncology company developing allosteric mutation-targeted therapies. Its similar market capitalization, clinical-stage profile, and focus on oncogene-driven cancers make it a relevant peer comparable.

Broad incumbents

  • Amgen: Amgen is a global biopharmaceutical incumbent with the commercialized KRAS G12C inhibitor Lumakras (sotorasib). It competes broadly in the RAS-mutated oncology space and serves as the dominant commercial benchmark for any approved RAS-pathway therapy in mCRC.
  • Roche: Roche is a global oncology leader with established colorectal cancer franchises including bevacizumab (Avastin). Its incumbent position in 1L mCRC combination therapy makes it a strategic reference for any new agent seeking to combine with FOLFIRI/bevacizumab.
  • Pfizer: Pfizer is a global biopharmaceutical incumbent that has invested $15M and serves as CRO partner for Cardiff's Phase 3 trial. While already a strategic partner rather than pure competitor, it overlaps in oncology drug development and remains a likely acquirer or commercialization partner if onvansertib succeeds.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cardiff Oncology social profiles

Digital presence

Cardiff Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cardiff Oncology leadership team

Management profile

Number of profiles

Profiles6 records

Cardiff Oncology funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cardiff Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardiff Oncology

What does Cardiff Oncology do?

Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 (Polo-Like Kinase 1) inhibitor designed to be combined with standard-of-care chemotherapy and targeted therapies across multiple cancer indications. The lead program targets first-line RAS-mutated metastatic colorectal cancer in combination with FOLFIRI/bevacizumab, advancing toward a global registrational Phase 3 trial, with additional investigator-initiated programs in pancreatic, breast, lung, ovarian, prostate cancers, and CMML.

Is Cardiff Oncology a public or private company?

Cardiff Oncology is a public company. It is classified as public and is currently operating.

When was Cardiff Oncology founded?

Cardiff Oncology was founded in 2013. It employs 11 to 50 people.

Where is Cardiff Oncology based?

Cardiff Oncology is headquartered in San Diego, United States, in the North America region.

Who are Cardiff Oncology's main competitors?

Direct peers on record are Revolution Medicines, Erasca, Mirati Therapeutics, BridgeBio Pharma, Foghorn Therapeutics, Kronos Bio and Black Diamond Therapeutics. Broad incumbents are Amgen, Roche and Pfizer.

Does Cardiff Oncology have an API?

No public API is recorded for Cardiff Oncology.

What industry is Cardiff Oncology in?

Cardiff Oncology's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaCardiff Oncology, Inc. (CRDF) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptCardiff Oncology presented at the UBS Global Biopharma Conference 2026, highlighting its PLK1 inhibitor for RAS-mutated metastatic colorectal cancer. The company received Fast Track designation for the indication and reported a Phase II trial showing an overall response rate of over 70% versus standard of care.Investing.comCardiff Oncology at UBS conference: phase iii push gains speedCardiff Oncology presented Phase II data for onvansertib plus FOLFOXIRI and bevacizumab in RAS-mutated metastatic colorectal cancer, showing an objective response rate above 70% versus 42% in control. The company received FDA Fast Track designation and plans a Phase III trial in Q1 2027, with potential for accelerated or full approval.Quiver QuantitativeCARDIFF ONCOLOGY ($CRDF) Releases Q3 2026 Earnings | CRDF Stock NewsCARDIFF ONCOLOGY reported Q3 2026 earnings of -$0.12 per share, beating estimates of -$0.15, and revenue of $171,000, up from $80,753. Insiders made four purchases in the past six months, while 32 institutional investors added shares and 73 reduced positions.Business & FinancialCardiff Oncology To Participate In The UBS Global Biopharma ConferenceCardiff Oncology will present at the UBS Global Biopharma Conference on November 16, 2026, in a fireside chat led by CEO Mani Mohindru. The company's lead asset, onvansertib, a PLK1 inhibitor, is in a Phase 2 trial for RAS-mutated mCRC. The webcast will be available for registration and replay.MarketBeatCardiff Oncology (CRDF) Expected to Announce Quarterly Earnings on ThursdayCardiff Oncology is expected to announce Q3 2026 earnings after market close on November 5th, with analysts projecting a loss of $0.1380 per share and revenue of $0.08 million. The company's stock opened at $0.90, and analysts have an average rating of Hold with a target price of $7.50.MarketWatchCardiff Oncology Names Alland Interim Chief Medical Officer as Sidhu Steps DownCardiff Oncology announced that Chief Medical Officer Roger Sidhu has stepped down, and Leila Alland was appointed interim chief medical officer. Alland previously served as CMO at PMV Pharma, Affimed, and Tarveda Therapeutics, and held leadership roles at Novartis, Bristol Myers Squibb, and AstraZeneca.The future of tradingCardiff Oncology Appoints Leila Alland as Interim Chief Medical OfficerCardiff Oncology appointed Leila Alland as interim chief medical officer, replacing Roger Sidhu, who stepped down. Alland previously served as chief medical officer at PMV Pharma, Affimed, and Tarveda Therapeutics.Business & FinancialCardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic LeukemiaCardiff Oncology received FDA orphan drug designation for onvansertib in chronic myelomonocytic leukemia (CMML). The designation supports development of a therapy for a rare disease affecting fewer than 200,000 U.S. patients. Onvansertib showed preliminary efficacy in about 40% of myeloproliferative CMML patients in a dose-ranging trial.Markets DailyAnalyzing Cardiff Oncology (NASDAQ:CRDF) and Xencor (NASDAQ:XNCR)Cardiff Oncology and Xencor are compared on analyst ratings, profitability, and valuation. Cardiff Oncology beats Xencor on 8 of 15 factors, with a consensus price target of $7.50 versus $34.00 for Xencor. Cardiff's higher possible upside suggests it is more favorable.American Banking and Market NewsNektar Therapeutics (NASDAQ:NKTR) vs. Cardiff Oncology (NASDAQ:CRDF) Head to Head SurveyNektar Therapeutics beats Cardiff Oncology on 8 of 15 factors in a head-to-head comparison. Nektar has higher institutional ownership (75.9% vs 16.3%) and a lower P/E ratio, while Cardiff shows higher potential upside from its $7.50 target price.